Health and Fitness Health and Fitness
Fri, December 16, 2011
[ Fri, Dec 16th 2011 ] - Market Wire
La secuenciacin del genoma ayuda a la investigacin de las enfermedades pblicas en Francia
Thu, December 15, 2011
[ Thu, Dec 15th 2011 ] - Market Wire
IQWIG Publishes Early Benefit Assessment for Pirfenidone
[ Thu, Dec 15th 2011 ] - Market Wire
The Ensign Group, Inc. Increases Quarterly Dividend by 9.1% to $0.06 Per Share
[ Thu, Dec 15th 2011 ] - Market Wire
Phase-III-Studie zur Evaluierung von REVLIMID in .. en multiplen Myelom der Hochrisikoklasse im Rahme
[ Thu, Dec 15th 2011 ] - Market Wire
Robbins Umeda LLP Announces an Investigation of SonoSite, Inc.
[ Thu, Dec 15th 2011 ] - Market Wire
Titan Medical Inc. Announces Overnight Marketed Financing
[ Thu, Dec 15th 2011 ] - Market Wire
FDA Classifies Voluntary Physician Advisory Lette .. one Defibrillation Leads as Class I Recall (URGEN
[ Thu, Dec 15th 2011 ] - Market Wire
Pacific Safety Products Awarded Cdn $1.1 Million Contract Amendment
[ Thu, Dec 15th 2011 ] - Market Wire
Kevin Sharer, Amgen Chairman and CEO, Announces P .. dway to Become CEO on May 23, 2012;; Share
[ Thu, Dec 15th 2011 ] - Market Wire
Gilead Sciences Submits Supplemental New Drug App .. g Administration for Truvada for Reducing the Ris
[ Thu, Dec 15th 2011 ] - Market Wire
Sequenom Named to NASDAQ Global Select Market
[ Thu, Dec 15th 2011 ] - Market Wire
Electrochem Announces Completion of Micro Power Electronics Acquisition
[ Thu, Dec 15th 2011 ] - Market Wire
FDA Approves Hologic's Cervista High Throughput Automation System for Cervical Cancer Screening
[ Thu, Dec 15th 2011 ] - Market Wire
Die US-Arzneimittelbehrde FDA hat einem beschleun .. KALYDECOa" (Ivacaftor) zugestimmt, das erste pote
[ Thu, Dec 15th 2011 ] - Market Wire
Amgen Announces 2012 First Quarter Dividend
[ Thu, Dec 15th 2011 ] - Market Wire
Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan
[ Thu, Dec 15th 2011 ] - Market Wire
A.M. Best Assigns Ratings to WellPoint Inc.as Shelf Registration
[ Thu, Dec 15th 2011 ] - Market Wire
FDA stemt in met prioriteitsbeoordeling van KALYD .. otentile geneesmiddel gericht op de onderliggende
[ Thu, Dec 15th 2011 ] - Market Wire
MabCure, Inc. Announces Completion of Its Ovarian Cancer Diagnostic Study in Thailand
[ Thu, Dec 15th 2011 ] - Market Wire
La FDA concede la revisione prioritaria per il KA .. o farmaco potenziale mirato per la proteina che c
[ Thu, Dec 15th 2011 ] - Market Wire
Covidien heeft plannen voor spin-off van farmaceutische activiteiten
[ Thu, Dec 15th 2011 ] - Market Wire
Glancy Binkow & Goldberg LLP Announces Investigation of SonoSite, Inc.
[ Thu, Dec 15th 2011 ] - Market Wire
Covidien planea una escisin de su unidad de negocio de productos farmacuticos
[ Thu, Dec 15th 2011 ] - Market Wire
Covidien planeja spin-off de segmento farmacutico
[ Thu, Dec 15th 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Announces I .. eaches of Fiduciary Duty by the Board of SonoSite
[ Thu, Dec 15th 2011 ] - Market Wire
Pomerantz Law Firm Investigates Claims on Behalf of Investors of SonoSite, Inc.
[ Thu, Dec 15th 2011 ] - Market Wire
Leisureworld Announces December Dividend
[ Thu, Dec 15th 2011 ] - Market Wire
The Law Firm of Levi &;; Korsinsky, LLP .. of Breaches of Fiduciary Duty by the Board of Sy
[ Thu, Dec 15th 2011 ] - Market Wire
LifePoint Selected for National Partnership for Patients Initiative
[ Thu, Dec 15th 2011 ] - Market Wire
FDA concede revisin prioritaria a KALYDECOa" (iva .. o potencial para la causa subyacente de la fibros

FDA concede revisin prioritaria a KALYDECOa" (ivacaftor), el primer medicamento potencial para la causa subyacente de la fibros


Published on 2011-12-15 08:00:53 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ ])--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) ha anunciado que la Agencia de Alimentos y Frmacos de EE.UU. (FDA en sus siglas en ingls) ha aceptado la solicitud de nuevo frmaco para KALYDECOTM (ivacaftor) y ha aceptado la solicitud de la empresa de una revisin prioritaria de seis meses. KALYDECO trata la protena defectuosa que causa la fibrosis qustica en un subgrupo de personas que viven con la enfermedad. En caso de ser aprobado, KALYDECO ser el primer tratamiento para la causa subyacente de la fibrosis qustica.

El comunicado en el idioma original, es la versin oficial y autorizada del mismo. La traduccin es solamente un medio de ayuda ydeber sercomparada con el texto en idioma original, que es la nica versin del texto que tendr validez legal.

Contributing Sources